06 March 2013
EMA/98737/2013
Committee for Medicinal Products for Veterinary Use (CVMP)

CVMP Monthly report of application procedures, guidelines and related documents

January 2013

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

Scientific advice requests

	95-10	2011	2012	2013	Total
Submitted	101	26	28	1	156
Advice given	91	24	29	0	144

Initial evaluation

	95-10	2011	2012	2013	Total
Full (Submitted)	140	8	12	3	160
Abridged/ generics (Submitted)	13	3	0	0	16
Withdrawals	13	0	1	0	14
Positive opinions	118	19	9	0	146
Negative opinions	1	0	0	0	1

Marketing authorisations

	95-10	2011	2012	2013	Total
Granted	111	24	8	0	143
Withdrawals	6	1	3	0	10
Not renewed	2	0	0	0	2

Extensions

	95-10	2011	2012	2013	Total
Submitted	75	7	8	0	90
Withdrawals	4	0	1	0	5
Positive opinions	55	4	10	1	69
Negative opinions	0	0	0	0	0

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8447
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Variations – applications submitted					
	95-10	2011	2012	2013	Total
Type IA	551	120	104	5	979
Type IB		101	96	2	
Type II	276	45	52	1	374
Transfers	22	3	2	0	27

Renewals					
	95-10	2011	2012	2013	Total
Submitted	75	14	10	1	99
Positive opinions	73	12	10	2	95
Negative opinions	0	0	0	0	0

Arbitrations and Community referrals					
	95-10	2011	2012	2013	Total
Referrals submitted	59	12	12	1	83
Opinions reached[1]	46 (6)	10	11 (1)	0	66 (7)

[1] Re-examination of opinions in brackets

Substances considered as not falling within the scope of Regulation (EC) No 470/2009					
	2010	2011	2012	2013	Total
Submitted	5	5	9	2	14
Agreed	0	10	6	2	16
Scientific advice recommended	0	0	0	1	0

MUMS/ Limited market classification				
	2011	2012	2013	Total
Positive with financial incentives	8	16	1	24
Positive without financial incentives	12	5	0	17
Negative	1	1	0	2

Establishment of MRLs for new substances					
	95-10	2011	2012	2013	Total
Submitted	73	1	1	0	75
Withdrawals	5	0	0	1	5
Positive opinions[2]	58	4	1	0	63
Negative opinions[3]	7	0	0	0	7

Extensions / modifications/extrapolations of MRLs					
	95-10	2011	2012	2013	Total
Submitted	110	13	5	1	128
Withdrawals	4	2	0	0	6
Positive opinions[2]	119	12	8 (2)	0	139
Negative opinions	6	0	0	0	6

[2] Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances with previously provisional maximum residue limits. Re-examination of opinions are indicated in brackets.

[3] Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

Arbitrations and Community referrals in 2013

Type of referral	• Date of clock start • CVMP opinion	• Product name • INN
Referral under Art. 35 of Directive 2001/82/EC	• 15/09/2011	• All long acting formulations for injection containing barium selenate for all food producing species • Barium selenate
Referral under Article 35 of Directive 2001/82/EC	• 12/04/2012	• All injectable and pour-on veterinary medicinal products containing doramectin that are intended for use in mammalian foodproducing species • Doramectin
Referral under Art. 34 of Directive 2001/82/EC	• 15/05/2012	• Micotil 300 Injectie and associated names • Tilmicosin
Referral under Article 33(4) of Directive 2001/82/EC	• 15/05/2012	• Florgane 300 mg/ml suspension for injection for cattle and pigs • Florfenicol
Referral under Article 33(4) of Directive 2001/82/EC	• 11/07/2012	• Strenzen 500/125 mg/g powder for use in drinking water for pigs • Amoxicillin/clavulanic acid
Referral under Article 35 of Directive 2001/82/EC	• 12/09/2012	• Suanovil 20 and associated names, Captalin and associated names and generic products thereof, including pending applications • Spiramycin
Referral under Article 35 of Directive 2001/82/EC	• 12/09/2012	• Dexadreson 2 mg/ml and associated names, and generic products thereof, including pending applications • Dexamethasone
Referral under Article 34 of Directive 2001/82/EC	• 10/10/2012	• Linco-Spectin 100 and its associated names • Lincomycin, spectinomycin
Referral under Article 34 of Directive 2001/82/EC	• 07/11/2012	• Baytril 2.5% injectable, Baytril 5% injectable and Baytril 10% injectable and their associated names • Enrofloxacin
Referral under Article 35 of Directive 2001/82/EC	• 07/11/2012	• All veterinary medicinal products containing enrofloxacin to be administered via the drinking water to chickens and/or turkeys

Type of referral	• Date of clock start • CVMP opinion	• Product name • INN
		• Enrofloxacin
Referral under Article 13 of Regulation (EC) No. 1234/2008	• 07/11/2012	• Soludox 500 mg/g powder for use in drinking water for pigs and chickens • Doxycycline hyclate
Referral under Article 30(3) of Regulation 726/2004	• 10/01/2013	• Lidocaine • Lidocaine

Guidelines and working documents in 2013

CVMP Safety

Reference number	Document title	Status
EMA/CVMP/SWP/398880/2012	Concept paper on genotoxic impurities	Adopted for consultation, January 2013 (End of consultation 30 April 2013)

Antimicrobials

Reference number	Document title	Status
EMA/CVMP/680258/2012	Concept paper on the development of a guideline on antimicrobial risk assessment	Adopted for consultation, January 2013 (End of consultation 30 April 2013)

International Harmonisation

Reference number	Document title	Status
VICH safety guideline	GL 23(R) on Safety: Studies to evaluate the safety of residues of veterinary drugs in human food: Genotoxicity testing	Adopted for consultation, January 2013 (End of consultation 31 March 2013)